Log In
BCIQ
Print this Print this
 

Trevyent

  Manage Alerts
Collapse Summary General Information
Company SteadyMed Ltd.
DescriptionProstacyclin analog treprostinil delivered via subcutaneous PatchPump technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPivotal
Standard IndicationHypertension
Indication DetailsTreat pulmonary arterial hypertension (PAH)
Regulatory Designation U.S. - Orphan Drug (Treat pulmonary arterial hypertension (PAH))
PartnerCardiome Pharma Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$12.3M

$3.0M

$9.3M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/29/2015

$12.3M

$3.0M

$9.3M

Get a free BioCentury trial today